EBUS TBNA Adequacy Assessment

Rapid on-site evaluation (ROSE) Solution for EBUS-TBNA that assists in adequacy assessment, diagnosis, and staging of lung cancer.

  • Rapid on-site evaluation (ROSE) for adequacy assessment of EBUS-TBNA aspirates.
  • Aids accurate and faster diagnosis and staging of lung cancer.
  • Analyses of whole slide images of conventional PAP (Papanicolaou) stained cytology smears.
  • Rapid onsite reporting with increased yield eliminating need for repeat procedures.
  • Optimised hospital stay and cost benefits to the patient.
  • Objective, evidence-based, and precise reports with fewer reviews.
  • 24/7 reporting with batch analysis.
  • Strong agreement of 0.92 (Cohen’s Kappa) with manual adequacy assessment by pathologists.

Tumor Identification and Localization

  • Algorithms for identification and segmentation of tumours in Hematoxylin and Eosin (H&E) stained whole slide images.
  • Algorithm features include: tumour identification, tumour/stroma segmentation and tumour localization.
  • Algorithm outputs validated for use on Non Small Cell Lung Carcinoma (NSCLC), breast carcinoma, pancreatic ductal adenocarcinoma and Head and Neck Squamous Cell Carcinoma (HNSCC).

ER/PR Quantification in Breast Carcinoma

  • Solution for accurate quantification of Estrogen/Progesterone receptor expression in breast carcinoma.
  • Aids disease stratification, prognostication and treatment decisions.
  • Segmentation and quantification models of tumour nuclei (positive and negative) to compute Allred scores.
  • Automated exclusion of in-situ malignancy from quantification.
  • Available as both semi-automated and automated workflow solutions.
  • Applicable on selected regions of interest (ROI) as well as whole slide images.
  • Improves accuracy, reproducibility and throughput of biomarker reporting.
  • Very good agreement with pathologists; Sensitivity, Precision, and F1-score of 0.99, 0.84, 0.91 respectively .

Her-2/Neu Quantification in IDC Breast

  • Solution for accurate quantification of Her-2/Neu expression in breast carcinoma.
  • Aids disease stratification, prognostication and treatment decisions.
  • Segmentation, quantification and grading of membrane positivity and intensity.
  • Automated exclusion of in-situ malignancy from quantification.
  • Available as both semi-automated and automated workflow solutions.
  • Applicable on selected regions of interest (ROI) as well as whole slide images .
  • Improves accuracy, reproducibility and throughput of biomarker reporting.
  • Strong agreement (0.91 Quadratic Kappa) with pathologists scoring.

Mitotic Index Quantification

  • Solution for mitotic index calculation.
  • Aids in prognostication, disease stratification and treatment decisions.
  • Applicable to Hematoxylin and Eosin based sections from breast carcinoma and Head & Neck Squamous Cell Carcinoma (HNSCC).
  • Analyses of “field of view” images as well as whole slide images.
  • Provides mitotic figure segmentation, classification, with improved accuracy of mitotic index calculation.
  • Strong and significant correlation (r = 0.91, p <.001) with manual assessment methods.

Gleason grading

  • Solution to aid accurate disease stratification in prostate carcinoma.
  • Automated tumour/stroma segmentation.
  • Pixel level Gleason grading as well as section level Gleason scoring.
  • Applicable on Tissue Micro Arrays (TMA), needle core biopsies, and radical resection specimens.

Pancreatic Intraepithelial Neoplasia (PanIN)

  • PanIN are microscopic epithelial precursor lesions of pancreatic ductal adenocarcinoma (PDAC) that serve as surrogate markers for invasive carcinoma elsewhere in the organ.
  • Solution for segmentation of PanIN lesions in Hematoxylin and Eosin (H&E) stained sections of human pancreas.
  • Accurate segmentation, grading of PanIN regions and invasive carcinoma in whole slide images of pancreas.
  • Sensitivity of 91.56% and Specificity of 85.68% in comparison with manual assessment by pathologists, for detection of PanIN.

Radical Prostatectomy Reporting

  • Solution for comprehensive reporting of Radical Prostatectomy specimens.
  • Gleason grading and staging with quantification of primary, secondary and tertiary patterns.
  • Segmentation and quantification of additional diagnostic, prognostic and predictive parameters to aid disease stratification, prognostication and treatment decisions.
  • Synoptic, customizable reporting formats.
  • Correlation with multi-modality data, to improve accuracy of reporting.

PDL-1 Quantification in NSCLC

  • PD-L1 protein expression has emerged as a biomarker with capabilities to predict patient response to immunotherapy.
  • Algorithm to aid patient selection for treatment with anti PD1/PDL-1 antibodies in lung carcinoma.
  • Networks for tumour segmentation, tumour cell detection and classification, with computation of the Tumour Proportion Score (TPS).
  • Both semi-automated and automated workflows available.
  • Applicable to selected regions of interest (ROI) as well as whole slide images.

Retinal Disease Classification and Grading

  • Solutions for retinal disease identification, diagnosis and grading.
  • Classification and grading of retinal diseases like Diabetic Retinopathy, Age-related Macular Degeneration, Glaucoma, and others, using colour fundus images.
  • Sensitivity for retinal disease classification across classes range between 88% to 99%.
NOTE: Unless otherwise stated, all products are “Research Use Only”; not for use in diagnostic procedures.
Cookies.

By contuining to use this website, you consent to the use of cookies in accordance with our Cookie Policy

Got It